More bad news for patients with Alzheimer’s disease.
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation jcm9144@gmail.com
SPECIAL REPORT #22.10
More bad news for patients with Alzheimer’s disease.
On June 16, Roche reported that crenezumab, a beta amyloid monoclonal antibody, failed in the closely watched Phase II API-ADAD trial. Roche stated that only a small numerical advantage had been observed but nothing that qualified as a statistical beneficial outcome in preventing or slowing down cognitive decline. This flop follows two previous phase III failures CREAD 1 and CREAD 2 in 2019.
The API-ADAD study, which was backed by Genentech, the National Institute on Aging (NIA), the Banner Alzheimer’s Foundation and the Neurosciences Group at the University of Antoquia in Columbia started in 2013, with 252 patients enrolled. The study aimed at showing positive preventive outcomes in Colombian families with autosomal dominant Alzheimer’s disease (ADAD) triggered by a Presenilin 1 E280A mutation. The University of Antioquia’s GNA Director and his team have identified 6,000 people across several families, of which 1,200 carry this specific mutation. The randomised study in that high-risk population was followed for up to eight years and was expected to demonstrate that crenezumab could slow down the appearance of cognitive disabilities or episodic memory deficits. The trial missed the two primary endpoints as well as the secondary endpoints.
“We did not get the results we wanted. We learned that we could do such a study. We learned many things about this molecule that we are continuing to look at very closely and we learned that we can accomplish the goal of trying to prevent Alzheimer’s disease” said Rachelle Doody global head of Neurodegeneration at Genentech.
Richard Hodes, Director of the NIA also pointed at ideas different from the beta amyloid hypothesis for tackling the disease, including combination therapies – a proposal we have made since several years- and other potential targets. The NIA is currently supporting 69 ongoing studies, of which 50% are amyloid-related and 50% are tackling other targets.
Roche is one of the very rare companies that have continued to invest and investigate drugs for Alzheimer’s disease. The company has still ongoing efforts for gantenerumab, another beta amyloid monoclonal antibody, with results from phase III clinical trials in more than 2,000 pateints expected for Q4 2022. Gantenerumab drug had earlier clinical failures.
This latest setback had a strong negative impact on AC Immune – the Swiss biotech which licensed the drug to Roche 16 years ag- with a share plunge of 28% on the day of the announcement. Other biotechnology companies involved in the Alzheimer field such as Alector, Anavex Life Sciences, Cortexyme, INmune Bio and Prothena Corporation also saw a strong decline of their value.
Prevention trials are considered as the next best chance to help patients with Alzheimer’s disease. “Our best opportunity to intervene successfully has been to move to earlier stages before damage -potentially irreversible damage- has been done” said Richard Hodes.
Paris, June 17, 2022.
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012